X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will enable the company to accelerate efforts across its pipeline, including specifically to evaluate the potential of its lead candidate CMTX-101 to combat infection in people with cystic fibrosis.
Lead Product(s): CMTX-101
Therapeutic Area: Infections and Infectious Diseases Product Name: CMTX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ohio Innovation Fund
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 05, 2024
Details:
CMTX-101 is an immune-enabling antibody therapy designed to treat serious bacterial infections and rapidly destroy the universal underlying structure of bacterial biofilms to undermine extracellular bacterial defenses.
Lead Product(s): CMTX-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CMTX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
CMTX-101 is an immune-enabling antibody therapy designed to precisely and rapidly destroy the universal underlying structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention.
Lead Product(s): CMTX-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CMTX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
CMTX-101 is an immune-enabling antibody therapy designed to precisely and rapidly destroy the universal underlying structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention.
Lead Product(s): CMTX-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CMTX-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
The grant is directed toward accelerated development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia. Clarametyx will be eligible for one further funding option supporting a first-in-human clinical trial.
Lead Product(s): CMTX-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CMTX-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 04, 2022
Details:
The study demonstrates the potential impact of addressing resistant or recalcitrant infections by targeting the universal stabilizing structure of bacterial biofilms.
Lead Product(s): Humanized monoclonal antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Renowned Columbus-based leaders and scientific innovators to develop novel technology platform discovered at Nationwide Children’s Hospital.
Lead Product(s): CMTX-001
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
